BioLargo Files Routine 8-K, Confirms OTCQB Listing
Ticker: BLGO · Form: 8-K · Filed: Jan 22, 2024 · CIK: 880242
Complexity: simple
Sentiment: neutral
Topics: compliance, corporate-governance, regulatory-filing
TL;DR
**BioLargo filed a routine 8-K, no major news, just standard compliance.**
AI Summary
BioLargo, Inc. filed an 8-K on January 22, 2024, primarily to disclose general information and confirm its status as a public company with Common Stock trading under the symbol BLGO on the OTCQB exchange. This filing doesn't contain new financial results or major corporate actions, but rather serves as a routine update. For investors, this means there's no immediate news impacting the stock price, but it reaffirms the company's compliance with SEC reporting requirements.
Why It Matters
This filing is a standard compliance update, confirming BioLargo's public trading status and basic company information, which is important for maintaining transparency and investor confidence.
Risk Assessment
Risk Level: low — This 8-K is a general information filing and does not contain any new material events that would introduce significant risk.
Analyst Insight
A smart investor would note this as a routine compliance filing, indicating no immediate material news. It's a good reminder to check for more substantive filings (like 10-K or 10-Q) for financial performance updates.
Key Numbers
- 000-19709 — Commission File Number (identifies BioLargo's registration with the SEC)
- 888 400-2863 — Business Phone Number (contact information for BioLargo, Inc.)
Key Players & Entities
- BIOLARGO, INC. (company) — the registrant filing the 8-K
- OTCQB (company) — the exchange where BioLargo's Common Stock is registered
- BLGO (company) — the trading symbol for BioLargo's Common Stock
- January 22, 2024 (date) — the date of the earliest event reported and filing date
- 000-19709 (dollar_amount) — Commission File Number
FAQ
What is the primary purpose of BioLargo, Inc.'s 8-K filing dated January 22, 2024?
The primary purpose of BioLargo, Inc.'s 8-K filing dated January 22, 2024, is to provide a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically under 'Regulation FD Disclosure' and 'Financial Statements and Exhibits' items, indicating a routine update of company information and compliance.
On which stock exchange is BioLargo, Inc.'s Common Stock traded, and what is its trading symbol?
BioLargo, Inc.'s Common Stock is registered on the OTCQB exchange, and its trading symbol is BLGO, as stated in the 'Securities registered pursuant to Section 12(b) of the Act' section of the filing.
What is BioLargo, Inc.'s business address and phone number as listed in the filing?
BioLargo, Inc.'s business address is 14921 Chestnut St., Westminster, California, 92683, and its telephone number is (888) 400-2863, according to the 'BUSINESS ADDRESS' section of the filing.
What is the company's Central Index Key (CIK) and State of Incorporation?
The company's Central Index Key (CIK) is 0000880242, and its State of Incorporation is Delaware, as detailed in the 'COMPANY DATA' section of the filing.
Does this 8-K filing indicate that BioLargo, Inc. is an emerging growth company?
No, the filing does not indicate that BioLargo, Inc. is an emerging growth company. The checkbox 'Indicate by check mark whether the registrant is an emerging growth company...' is not marked, implying it does not consider itself one for the purposes of this filing.
Filing Stats: 607 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-01-22 10:15:14
Filing Documents
- blgo20240121_8k.htm (8-K) — 28KB
- ex_617441.htm (EX-99.1) — 9KB
- 0001437749-24-001796.txt ( ) — 166KB
- blgo-20240122.xsd (EX-101.SCH) — 3KB
- blgo-20240122_def.xml (EX-101.DEF) — 11KB
- blgo-20240122_lab.xml (EX-101.LAB) — 14KB
- blgo-20240122_pre.xml (EX-101.PRE) — 11KB
- blgo20240121_8k_htm.xml (XML) — 2KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.   On January 22, 2024, BioLargo, Inc. published the press release which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.   The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the press release attached as Exhibit 99.1 to this Current Report shall not be incorporated by reference into any filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures. For important information about forward looking statements, see the information under the heading "Safe Harbor Act" in Exhibit 99.1 attached hereto.    
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.   (d)      Exhibits.     Exhibit No. Description 99.1 Press release 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)    
SIGNATURES
SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.       Date: January 22, 2024 BIOLARGO, INC. By:  /s/  Dennis P. Calvert Dennis P. Calvert President and Chief Executive Officer